<DOC>
	<DOC>NCT01559038</DOC>
	<brief_summary>The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult &gt;= 18 years old Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as well as active psoriatic skin lesions or confirmed history of psoriasis Inadequate response or nontolerant to current diseasemodifying antirheumatic drugs (DMARD) based treatment for PsA Currently participating in another prospective study including controlled clinical trials and observational studies Patient cannot or will not sign informed consent Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated Previous treatment with antitumor necrosis factor (antiTNF) or other biologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Assessing Effectiveness in Psoriatic Arthritis</keyword>
</DOC>